Taiwan’s record export orders in July 2026, driven by AI related tech demand, highlight how quickly growth stories can build when global demand aligns with strong business execution. Investors who focus on fast growing stocks with high insider ownership tap into companies where management has skin in the game. This article highlights three stocks from that screener and explains why they deserve a closer look.
The three stocks below are just a starting sample from this idea. The full screen surfaced 105 more companies with similarly compelling growth and insider ownership stories that are not covered here. To identify and analyze the ones that best fit your style, head straight into the Fast Growing Stocks With High Insider Ownership screener.
Overview: Rubicon Research is a specialty pharmaceutical company headquartered in Mumbai that develops and commercialises medicines across areas such as pain management, cardiovascular and central nervous system disorders, with growth anchored in its proprietary RubiReten gastro retentive and RubiSRL sustained release drug delivery platforms. These technologies support new and extended release formulations that can be licensed or partnered globally, which is a key link to the fast growth and insider aligned optimism behind this screener theme.
Operations: Rubicon Research generates almost all of its ₹17,539.56 million revenue from pharmaceutical products and related services, with around ₹17,371.58 million coming from the USA and only a small portion from India and other markets.
Market Cap: ₹297.76 billion
Rubicon Research may appeal if you are looking for a fast growing pharma business where insider optimism is tied to tangible drug delivery platforms rather than one off products. The RubiReten and RubiSRL technologies give the company a way to keep rolling out extended release medicines and licensing deals. This has supported recent earnings growth and improving profit margins. At the same time the stock trades on a very rich valuation and relies heavily on external borrowing, so expectations are high and setbacks in the pipeline or funding conditions could affect sentiment. If you want exposure to specialty pharma with a clear product engine, Rubicon Research is worth a closer look.
Rubicon Research’s rich valuation and heavy borrowing suggest a situation in which product platforms and expectations might be moving in different directions. Get the full picture in the 2 key rewards and 2 important warning signs (1 is major!)
Rubicon Research and the other two stocks in this article all came from a single screen, but the real edge comes when you tailor the filters to your own approach. Use our flexible Screener to blend growth, valuation and balance sheet filters, or tap into any of our curated Investing Ideas.
Overview: Meesho runs a value focused e commerce marketplace in India that connects millions of small and medium sellers with consumers across categories such as apparel, home and kitchen, beauty, electronics and groceries. Its fast growing marketplace and related advertising, logistics and content commerce services are the clearest link to the fast growth and insider aligned theme.
Operations: Meesho generates essentially all of its ₹138.35 billion revenue in India, with ₹138.19 billion coming from its core marketplace segment and a very small contribution from new initiatives.
Market Cap: ₹910.05 billion
Meesho attracts attention because its mass market marketplace model is built for rapid GMV and user growth in smaller cities and rural areas. Higher margin levers such as advertising and Meesho Mall are intended to improve earnings quality over time. Recent results show revenue of ₹38,264.03 million in Q1 2026 and a narrowing net loss of ₹1,328.35 million, which supports the idea of improving unit economics even as the platform scales. At the same time, a short cash runway of less than a year, reliance on higher risk funding and a relatively new leadership team keep execution and financing risk firmly on the table. For investors who can balance these trade offs, Meesho offers a high growth marketplace story that still has plenty left to prove.
Meesho’s rapid GMV engine and tightening losses suggest a story that many investors may only be half reading. Get the full analysis report for Meesho and see how the short cash runway could change the script.
Overview: Bajel Projects is an EPC contractor that designs, builds and commissions extra high voltage transmission lines and power distribution infrastructure in India and overseas. Its grid linked projects and related manufacturing of poles and substation structures provide a clear link to the electrification theme behind this screener.
Operations: Bajel Projects generates all of its ₹27,508 million revenue from power transmission and power distribution projects.
Market Cap: ₹20.85 billion
Bajel Projects may be of interest to investors seeking direct exposure to the build out of power grids, from ultra high voltage lines for PowerGrid and international clients to substations for data centers. The company has announced a series of mega and ultra mega EPC orders through mid 2026. The trade off is thin current margins, heavy reliance on external borrowing and a relatively new board and management team, which raise questions about how smoothly any future expansion can be delivered. For investors comfortable with these risks, Bajel Projects represents a focused grid expansion story where the market already reflects expectations for strong execution.
Bajel Projects is bidding for mega grid work while margins and borrowing keep many investors cautious. Get the full 2 key rewards and 1 important warning sign and see whether the order book is masking something crucial.
Markets move fast and early movers often catch breakout stories while they are still under the radar for now. Scan fresh ideas before the momentum is gone and consider acting while opportunities are still developing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com